Home > Boards > US Listed > Biotechs > Clovis Oncology, Inc. (CLVS)
Followed By 403
Posts 53826
Boards Moderated 26
Alias Born 09/20/2001

Wednesday, February 16, 2022 8:02:20 AM

Re: None

Post# of 783
Quote:
Clovis Oncology Inc. [CLVS] Revenue clocked in at $156.10 million, down -24.35% YTD: What’s Next?
By Caleb Clifford -February 10, 2022
Clovis Oncology Inc. [NASDAQ: CLVS] jumped around 0.16 points on Wednesday, while shares priced at $2.05 at the close of the session, up 8.47%. The company report on January 10, 2022 that Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021.

Estimated $35.5M – $36.1M in Rubraca® (rucaparib) global sales for Q4 2021 and $148.3M – $148.9M for FY 2021.

Continuing impact on ovarian cancer diagnoses and treatments from COVID-19.

Clovis Oncology Inc. stock is now -24.35% down from its year-to-date (YTD) trading value. CLVS Stock saw the intraday high of $2.09 and lowest of $1.91 per share. The company’s 52-week high price is 10.74, which means current price is +19.88% above from all time high which was touched on 01/03/22.

Compared to the average trading volume of 4.30M shares, CLVS reached a trading volume of 7530240 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Clovis Oncology Inc. [CLVS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $5.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2020. The new note on the price target was released on April 27, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $6, while BofA/Merrill analysts kept a Underperform rating on CLVS stock. On January 08, 2020, analysts decreased their price target for CLVS shares from 36 to 27.

The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.20, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 1.66.

How has CLVS stock performed recently?
Clovis Oncology Inc. [CLVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.04. With this latest performance, CLVS shares dropped by -20.85% in over the last four-week period, additionally sinking by -57.38% over the last 6 months – not to mention a drop of -78.51% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 43.50, with the RSI for the last a single of trading hit 48.42, and the three-weeks RSI is set at 41.48 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 2.5900, while it was recorded at 1.8800 for the last single week of trading, and 4.3100 for the last 200 days.

Clovis Oncology Inc. [CLVS]: Deeper insight into the fundamentals
Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.00.




https://dbtnews.com/2022/02/10/clovis-oncology-inc-clvs-revenue-clocked-in-at-156-10-million-down-24-35-ytd-whats-next/
Recent CLVS News

Green Battery Minerals Receives Assays from Drilling into Graphite Outcrops on Zone 1. Intersecting 19.5 metres of 35.52% Grade Graphite and 51.20 meters of 22.61% Grade Graphite. CZSVF Aug 12, 2022 6:07 PM

Alliance Creative Group (ACGX) Reports Revenue of $2,974,489 for Second Quarter of 2022 ACGX Aug 12, 2022 12:40 PM

Progressive Care Reports Second Quarter 2022 Results Highlighted by 4% Growth to $10.0 Million in Revenue RXMD Aug 12, 2022 10:21 AM

PJET Bullish Investment Message Garners New Investment Interest PJET Aug 12, 2022 9:53 AM

VAYK Real Estate Fintech Strategy Builds Momentum and Explores Stock Buyback VAYK Aug 12, 2022 9:46 AM

Branded Legacy, Inc. Eliminates Over 430 Thousand In Debt In 2022 BLEG Aug 12, 2022 9:15 AM

InnerScope Hearing Technologies (OTC: INND) Reports Record Revenues for a Profitable Q2 2022 INND Aug 12, 2022 8:00 AM

Pro Music Rights, Inc., one of the world's largest music licensing companies, announces that it intends to Release its Financials by August 19, 2022 NUVG Aug 11, 2022 11:11 AM

AXTG Partner with Save Planet Earth to digitize and plant 100 million trees with NFTs AXTG Aug 11, 2022 10:15 AM

PURA Announces New Development Expanding Cannabis Market Opportunity PURA Aug 11, 2022 9:34 AM

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis KTTA Aug 11, 2022 8:35 AM

SinglePoint Acquires Frontline Power Solutions, a Multi-State Licensed Energy Services Company SING Aug 11, 2022 8:30 AM

Pacific Booker Minerals Inc. Announces AGM Results and Project Update PBMLF Aug 11, 2022 7:30 AM

GALILEO ANNOUNCES THE START OF REVENUE GENERATION AND ITS EXPANSION PLAN. MDRM Aug 10, 2022 3:23 PM

ResGreen Powers Up - Introduces Wireless Battery Charging for its Fleet of Mobile Robots RGGI Aug 10, 2022 10:53 AM

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y